and its spot is no doubt intended to help it stand out to a viewership that has already been inundated with dozens of commercials from Novo Nordisk, the manufacturer of Ozempic and Wegovy ...

Shares of Hims & Hers Health (NYSE:HIMS) rallied to reach an all-time high on Friday as the telehealth firm is set to debut its controversial TV commercial 'Sick of the System' during the upcoming ...

Big Pharma often turns to NFL games to hawk their blockbuster treatments, but drug makers have typically been hesitant to ...

For the third year in a row, the hundreds of millions of dollars poured into commercials for ... hold off on traditional TV advertising for its obesity juggernaut Wegovy in 2023.

Kathy Hochul is proposing to increase access to popular diabetes medications such as Wegovy and Ozempic for ... with an objective of "requiring commercial insurance policies to provide ...

He has seen the Wegovy TV commercials, and a few of his friends who have struggled with their weight swear it’s the real deal. Bob makes an appointment with his family doctor because he needs a ...

That left room for Johnson & Johnson’s Tremfya to jump up to the second spot, while Novo Nordisk’s megapopular obesity med Wegovy—a recent addition to iSpot.TV’s pharma ad spending ...

Now, a new study finds that Ozempic, along with similar drugs such as Wegovy, has had a broad “economic and societal impact” because of “noticeable shifts in dietary behavior.” The study ...

However, the selection of Ozempic and Wegovy for the second round of bargaining could prompt insurers in the commercial market to push for better deals for their policyholders. The high cost of ...

Seal and Becky G star alongside Mountain Dew’s newly minted spokesperson the Mountain Dude, who was introduced last year.

WASHINGTON — (AP) — Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to Medicare's list of medications that will be negotiated directly between the government and ...

Together, those 25 drugs account for a third of Medicare spending on prescriptions, Becerra said. Ozempic and Wegovy, in particular, have been scrutinized for their high out-of-pocket costs ...